Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

by Alastair J King, Marc R Arnone, Maureen R Bleam, Katherine G Moss, Jingsong Yang, Kelly E Fedorowicz, Kimberly N Smitheman, Joseph A Erhardt, Angela Hughes-Earle, Laurie S Kane-Carson, Robert H Sinnamon, Hongwei Qi, Tara R Rheault, David E Uehling, Sylvie G Laquerre
Published 2013-01-01